An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers

Trial Profile

An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Emricasan (Primary)
  • Indications Alcoholic hepatitis; Hepatic fibrosis; Liver failure; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 23 Apr 2015 According to a Conatus Pharmaceuticals media release, results from this trial are being presented at The International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 11 Mar 2015 According to a Conatus Pharmaceuticals media release, aggregate top-line results from this and two other phase I and phase IIb trials (n=73) in five distinct organ impairment patient populations were released in Jan 2015.
    • 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top